002349.SHE Nantong Jinghua Pharmaceutical Co Ltd
- Market cap
- CNY 5.68B
- P/E
- 24.4x
- P/B
- 1.97x
- ROE
- 8.8%
- Dividend yield
- 1.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002349.SHE undervalued?
Graham number002349.SHE trades 46.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nantong Jinghua Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Nantong Jinghua Pharmaceutical Co Ltd yet.
Nantong Jinghua Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers active pharmaceutical ingredients (APIs) and intermediates, chemical and pharmaceutical intermediates, Chinese medicinal herbs and materials, health products, and Western medicine products. It also provides Jidesheng antivenomous tablets, Nantong Wang's baby health pill, Ningning…
Full company profileNantong Jinghua Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nantong Jinghua Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 881M | 1.12B | 1.35B | 1.16B | 1.28B | 1.36B | 1.57B | 1.51B | 1.40B | 1.46B | 1.48B |
| Gross Profit | 434M | 556M | 646M | 419M | 586M | 619M | 726M | 731M | 682M | 758M | 787M |
| Operating Income | 194M | 171M | 293M | -498M | 63.3M | 181M | 251M | 331M | 295M | 284M | 339M |
| EBITDA | 268M | 286M | 377M | -393M | 168M | 293M | 365M | 417M | 370M | 385M | 356M |
| Net Income | 165M | 175M | 230M | -394M | 111M | 161M | 212M | 248M | 213M | 219M | 253M |
| EPS | 0.20 | 0.21 | 0.28 | -0.48 | 0.14 | 0.20 | 0.26 | 0.30 | 0.26 | 0.26 | 0.30 |
| Balance Sheet | |||||||||||
| Total Assets | 2.53B | 3.24B | 3.40B | 2.94B | 3.16B | 3.20B | 3.04B | 3.19B | 3.30B | 3.57B | 3.68B |
| Total Liabilities | 228M | 594M | 705M | 794M | 669M | 629M | 418M | 381M | 345M | 421M | 379M |
| Shareholders' Equity | 2.15B | 2.28B | 2.28B | 1.85B | 2.11B | 2.24B | 2.40B | 2.44B | 2.58B | 2.75B | 2.88B |
| Cash & Short-term Investments | 386M | 388M | 241M | 336M | 696M | 865M | 1.06B | 1.24B | 1.12B | 855M | 728M |
| Total Debt | 21.1M | 290M | 414M | 511M | 202M | 195M | 22.6M | 21.4M | 10.6M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 344M | 75.9M | 83.4M | 285M | 328M | 306M | 358M | 291M | 311M | 341M | - |
| Capital Expenditure | 245M | 441M | 160M | 255M | 118M | 80.5M | 61.6M | 28.4M | 30.9M | 20.3M | 31.7M |
| Free Cash Flow | 98.7M | -365M | -76.8M | 30.0M | 210M | 225M | 297M | 263M | 280M | 321M | 200M |
| Ratios | |||||||||||
| ROE | 7.7% | 7.7% | 10.1% | -21.3% | 5.3% | 7.2% | 8.8% | 10.1% | 8.2% | 8.0% | 8.8% |
| ROA | 6.5% | 5.4% | 6.8% | -13.4% | 3.5% | 5.0% | 7.0% | 7.8% | 6.4% | 6.1% | 6.9% |
| Net Profit Margin | 18.7% | 15.6% | 17.0% | -34.0% | 8.7% | 11.8% | 13.5% | 16.4% | 15.2% | 15.0% | 17.1% |
| Debt to Equity | 0.01x | 0.13x | 0.18x | 0.28x | 0.10x | 0.09x | 0.01x | 0.01x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nantong Jinghua Pharmaceutical Co Ltd dividends
- Dividend yield
- 1.15%
- Forward dividend
- 0.09 CNY
- Payout ratio
- 29.8%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 65.2M | 0.08 | 29.8% |
| 2024 | CNY 75.5M | 0.09 | 35.5% |
| 2023 | CNY 66.0M | 0.08 | 26.6% |
| 2022 | CNY 48.9M | 0.06 | 23.0% |
| 2021 | CNY 44.5M | 0.05 | 27.7% |
| 2020 | CNY 20.0M | 0.02 | 18.0% |
| 2019 | CNY 61.0M | 0.07 | - |
| 2018 | CNY 57.4M | 0.07 | 25.0% |
| 2017 | CNY 69.1M | 0.08 | 39.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Mar 14, 2017.
Who owns Nantong Jinghua Pharmaceutical Co Ltd
- Insiders 39.02%
- Institutions 1.28%
- Public & others 59.70%
- Shares outstanding 831M
- Free float 507M
Nantong Jinghua Pharmaceutical Co Ltd company profile
- Company name
- Nantong Jinghua Pharmaceutical Co Ltd
- Ticker
- 002349.SHE
- ISIN
- CNE100000L14
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Feb 3, 2010
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,462
- Fiscal year end
- December
- Address
- Building A, Guocheng Life Plaza Office Building, Nantong, China, 226001
- Phone
- 86 513 8560 9118
- Website
- ntjhzy.com
About Nantong Jinghua Pharmaceutical Co Ltd
Jinghua Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers active pharmaceutical ingredients (APIs) and intermediates, chemical and pharmaceutical intermediates, Chinese medicinal herbs and materials, health products, and Western medicine products. It also provides Jidesheng antivenomous tablets, Nantong Wang's baby health pill, Ningning ZhengChaihu granules, Dachaihu granules, Gubenkechuan tablets, dizziness treatment syrup, and Jinqiaomai tablets; and APIs, such as phenobarbital, primidone, fluorouracil, phenylbutazone, flucytosine, piroxicam, tenoxicam, and propylthiouracil. In addition, the company engages in enterprise management; technical services; goods and technology import and export; chemical wholesale; pharmaceutical retail; medical devices equipment sales; provision of cosmetics and skincare products; and investment activities. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. Jinghua Pharmaceutical Group Co., Ltd. was founded in 1957 and is headquartered in Nantong, China.
Nantong Jinghua Pharmaceutical Co Ltd management
6- Mr. Jian ChengGM, CFO & Director · born 1979
- Mr. Yuxiang WuVice Chairman · born 1969
- Mr. Jianfeng WangBoard Secretary · born 1977
- Mr. Qianyong ZhuDeputy General Manager · born 1970
- Ms. Yan Juan ShenDeputy General Manager · born 1976
- Li ZhaoAccounting Supervisor